Affiliations 

  • 1 Guangdong Mental Health Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China
  • 2 Unit of Psychiatry, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macao SAR, China; Center for Cognition and Brain Sciences, Faculty of Health Sciences, University of Macau, Macao SAR, China; Department of Neurosurgery, The Affiliated Hospital of Southwest Medical University, Neurosurgery Clinical Medical Research Center of Sichuan Province, Academician (Expert) Workstation of Sichuan Province, Sichuan, China
  • 3 The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders Beijing Anding Hospital & the Advanced Innovation Center for Human Brain Protection, Capital Medical University, School of Mental Health, Beijing, China
  • 4 Department of Pharmacy, Taipei City Hospital, Taipei, Taiwan
  • 5 Department of Psychiatry, Taipei City Hospital and Psychiatric Center, Taipei, Taiwan
  • 6 Mintoharjo Hospital, Jakarta, Indonesia
  • 7 Pushpagiri Institute of Medical Sciences, Tiruvalla, Kerala, India
  • 8 Suanprung Psychiatric Hospital, Chian Mai, Thailand
  • 9 Department of Psychiatry & Mental Health, Hospital Tuanku Fauziah, Kangar, Perlis, Malaysia
  • 10 Pakistan Psychiatric Research Centre, Fountain House, Lahore, Pakistan
  • 11 Thanh Hoa Provincial Psychiatric Hospital, Thanh Hoa, Vietnam
  • 12 Department of Psychiatry, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
  • 13 Institute of Mental Health, Buangkok Green Medical Park, Singapore
  • 14 Department of Mental Health, University of Medicine, Magway, Myanmar
  • 15 Department of Psychiatric Epidemiology, Shanghai Mental Health Center, Shanghai, China
  • 16 Department of Psychiatry, Hanyang University, Seoul, Republic of Korea
  • 17 National Institute of Mental Health, Dhaka, Bangladesh
  • 18 National Institute of Mental Health, Angoda, Sri Lanka
  • 19 Department of Psychiatry, Chinese University of Hong Kong, Hong Kong SAR, China
  • 20 Association for the Improvement of Mental Health Programs, Geneva, Switzerland
  • 21 Department of Pharmacology, National University of Singapore, Singapore
  • 22 Chiayi Chang Gung Memorial Hospital and School of Medicine, Chang Gung University, Chiayi, Taiwan
  • 23 International Center for Medical Research, Kobe University School of Medicine, Kobe, Japan
  • 24 Department of Psychiatry, Taipei City Hospital and Psychiatric Center, Taipei, Taiwan; Department of Psychiatry, School of Medicine, Taipei Medical University, Taipei, Taiwan
  • 25 Department of Psychiatry, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
  • 26 Department of Psychiatry, University of Melbourne, Melbourne, Victoria, Australia
  • 27 University of Notre Dame Australia, Fremantle, Australia; Division of Psychiatry, Medical School, University of Western Australia, Perth, Australia
  • 28 Unit of Psychiatry, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macao SAR, China; Center for Cognition and Brain Sciences, Faculty of Health Sciences, University of Macau, Macao SAR, China. Electronic address: xyutly@gmail.com
Asian J Psychiatr, 2019 Oct;45:74-80.
PMID: 31520884 DOI: 10.1016/j.ajp.2019.08.010

Abstract

OBJECTIVE: Regular surveys are important to monitor the use of psychotropic medications in clinical practice. This study examined the psychotropic prescription patterns in adult Asian schizophrenia patients based on the data of the Research on Asian Psychotropic Prescription (REAP) 2016 survey.

METHODS: This cross-sectional survey across 15 Asian countries/territories collected socio-demographic and clinical data with standardized procedures between March and May 2016. The socio-demographic and clinical characteristics of the patients were recorded with a standardized questionnaire.

RESULTS: Altogether 3,537 adult patients with schizophrenia were consecutively screened and enrolled in the survey. The mean age was 38.66 ± 11.55 years and 59.7% of the sample were male. The mean dose of antipsychotics in chlorpromazine equivalents (CPZeq) was 424 ± 376 mg/day; 31.3% and 80.8% received first- and second- generation antipsychotics, respectively and 42.6% had antipsychotic polypharmacy, 11.7% had antidepressants, 13.7% had mood stabilizers, 27.8% had benzodiazepines, and 45.6% had anticholinergics.

CONCLUSIONS: Psychotropic prescription patterns in Asian adult patients with schizophrenia varied across countries. Regular surveys on psychotropic medications for schizophrenia are important to monitor pharmacotherapy practice in Asia.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.